Key result
Protocatechuic acid improves flow-mediated dilation by ~1.8% vs. placebo in hypercholesterolemia.
Why the study?
Protocatechuic acid has been shown to improve endothelial function in mice, but its effects on endothelial function and HDL functionality in humans are unknown.
Does protocatechuic acid supplementation improve brachial artery flow-mediated dilation and HDL functionality in adults with hypercholesterolemia?
RCT (n=150)
Double-blind
Stratified permuted block randomization
Yes
Does protocatechuic acid supplementation improve brachial artery flow-mediated dilation and HDL functionality in adults with hypercholesterolemia?
Daily supplementation with 20 mg of protocatechuic acid for 12 weeks improves endothelial function and enhances the atheroprotective functionality of HDL in adults with hypercholesterolemia.
Supports endothelial benefit from protocatechuic acid in hypercholesterolemia; extends murine data to humans but leaves outcome trials needed.
Background: High-density lipoprotein (HDL) exerts atheroprotective properties, partially by maintaining endothelial function. Protocatechuic acid (PCA) has been shown to improve endothelial function in mice. However, whether PCA improves endothelial function in humans is currently unknown. Our studies aimed to evaluate the effects of PCA on endothelial function and HDL concentration, subclass distribution, and functionality in humans. Methods: A double-blind, randomized, placebo-controlled trial was conducted in 150 hypercholesterolemic participants (aged 35–65 y) daily receiving 20 mg PCA or placebo capsules for 12 weeks. Endothelial function [brachial artery flow-mediated dilation (FMD)], serum cyclic guanosine monophosphate (cGMP), HDL concentration, subclass distribution (pre-β-HDL, HDL3, HDL2), and functionality [endothelial nitric oxide synthase (eNOS) activity] were tested at baseline, 6 weeks, and 12 weeks. Results: PCA consumption for 12 weeks significantly improved brachial artery FMD [1.77% (95% CI: 1.46 to 2.08)] and increased cGMP [11.72 pmol/L (95% CI: 6.16 to 17.28)] as compared to the placebo treatment, along with increased HDL3, decreased HDL2, and non-significantly changed in HDL and pre-β-HDL. PCA consumption also increased eNOS activity of HDL [0.39 (95% CI: 0.29 to 0.49)]. In the PCA group, the changes in HDL functionality on eNOS activity were positively correlated with the changes in brachial artery FMD, cGMP, and HDL3, whereas negatively correlated with HDL2. Conclusions: PCA consumption improves endothelial function and HDL functionality in humans with hypercholesterolemia, with accompanying shifts in HDL subclass distributions. These findings are hypothesis-generating and require confirmation in larger, long-term trials.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted an RCT in Hypercholesterolemia (n=150). Protocatechuic acid (PCA) vs. Placebo was evaluated on Change in brachial artery flow-mediated dilation (FMD) (MD 1.77, 95% CI 1.46 to 2.08, p=<0.001). Daily supplementation of 20 mg protocatechuic acid for 12 weeks significantly improved brachial artery flow-mediated dilation by a mean difference of 1.77% compared to placebo in adults with hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: